Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06365541
Status:
RECRUITING
Last Update Posted:
2024-04-15
First Post:
2024-04-09
Brief Title:
The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients
Sponsor:
The Peoples Hospital of Gaozhou
Organization:
The Peoples Hospital of Gaozhou
Study Overview
Official Title:
Exploring the Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients an Open Prospective and Self-controlled Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dialysis patients have a higher incidence of cardiovascular events and require more effective measures to delay the progression of heart failure Many studies have shown that dapagliflozin has cardioprotective effect but most studies focus on non-dialysis patients with eGFR more than 20mlmin173m2 However the data on patients with eGFR less than 20mlmin173m2 or dialysis patients especially peritoneal dialysis patients is less Exploring the efficacy and safety of Dapagliflozin in improving heart failure in dialysis patients is of great clinical significance
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None